In addition, treatment with AGK2, a selective inhibitor of SIRT2, blocked the therapeutic action of nicotinamide riboside (NR) against NAFLD pathologies and the downregulation of inflammatory and fibrotic factors mediated by NR [47]. The gene discussed is SIRT2; the disease is metabolic dysfunction-associated steatotic liver disease.